European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status:
Completed
Trial end date:
2019-02-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with
metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as
measured by time to treatment failure defined as the time from baseline (treatment
initiation) to treatment discontinuation of enzalutamide for any reason including disease
progression, skeletal related events, treatment toxicity, patient preference, or death.